A lit­tle less than 2 months af­ter pen­ny stock play­er Spec­trum Phar­ma­ceu­ti­cals took out the bud­get ax to chop off about a third of its staff, the CFO is now on the way out as well.

In an SEC fil­ing the com­pa­ny re­port­ed that Kurt Gustafson is off in search of new op­por­tu­ni­ties.

There’s no ex­pla­na­tion, just the stan­dard:

Mr. Gustafson’s de­par­ture is not re­lat­ed to any dis­agree­ment with the Com­pa­ny or its au­di­tors on any mat­ter re­lat­ing to the Com­pa­ny’s fi­nan­cial and ac­count­ing op­er­a­tions, poli­cies or prac­tices.

Spec­trum an­nounced right af­ter the start of the new year that it was cir­cling the wag­ons around 2 key as­sets, in­clud­ing their drug Rolon­tis, which was hit by a CRL last sum­mer. The biotech cit­ed man­u­fac­tur­ing is­sues as the rea­son for the re­jec­tion, vow­ing to get that right.

The stock was trad­ing at 69 cents Wednes­day af­ter­noon, down 9%.

Paul McKenzie took over as CEO of Australian pharma giant CSL this month, following in the footsteps of long-time CSL vet Paul Perreault.

With an eye on mRNA, and quickly commercializing its new, $3.5 million-per-shot gene therapy for hemophilia B, McKenzie and chief medical officer Bill Mezzanotte answered some questions from Endpoints News this afternoon about where McKenzie is going to take the company and what advances may be coming to market from CSL’s pipeline. Below is a lightly edited transcript.

Otonomy may be shutting down, but the lessons learned there will live on at another biotech working on new treatments for hearing loss.

San Francisco-based Spiral Therapeutics has bought certain assets related to three of Otonomy’s programs, ranging from data, patent rights, and know-how to inventory. That includes data around Otonomy’s twice-failed lead program, OTO-104 (Otividex), a sustained-exposure formulation of dexamethasone.

Boehringer Ingelheim reported human pharma sales of €18.5 billion on Wednesday, led by type 2 diabetes and heart failure drug Jardiance and pulmonary fibrosis med Ofev. Jardiance sales reached €5.8 billion, growing 39% year over year, while Ofev took in €3.2 billion, notching its own 20.6% annual jump.

However, Boehringer is also looking ahead with its pipeline, estimating “In the next seven years the company expects about 20 regulatory approvals in human pharma.”

The FDA today approved Emergent BioSolutions’ Narcan brand naloxone nasal spray for over-the-counter sales. The nod was expected and comes on the heels of a unanimous 19-0 advisory committee vote in favor of approval last month.

The move to OTC means the opioid overdose reversal agent will now be available on grocery, convenience and gas stations shelves, as well as potentially for purchase online.